Oncology Care Model

Oncology Care Model
Name	Oncology Care Model
Established	2016
Agency	Centers for Medicare & Medicaid Services
Country	United States

Oncology Care Model

The Oncology Care Model is a United States Medicare payment initiative launched by the Centers for Medicare & Medicaid Services to redesign oncology care delivery and payment. It sought to address cost and quality for beneficiaries receiving chemotherapy by aligning incentives across practices, payers, and suppliers. The model intersected with major policy efforts and stakeholders in American health policy and cancer care.

Overview

The program built on prior payment reforms such as Medicare Shared Savings Program, Bundled Payments for Care Improvement, and Medicare Access and CHIP Reauthorization Act of 2015 while engaging major actors including American Society of Clinical Oncology, National Comprehensive Cancer Network, Community Oncology Alliance, American Cancer Society, and large provider organizations like MD Anderson Cancer Center, Mayo Clinic, Johns Hopkins Hospital, Cleveland Clinic, and Dana-Farber Cancer Institute. It responded to concerns raised by reports from Institute of Medicine, analyses from Centers for Disease Control and Prevention, and policy reviews in outlets connected to Kaiser Family Foundation, Commonwealth Fund, Robert Wood Johnson Foundation, and Brookings Institution. The design reflected legal and regulatory frameworks including Social Security Act provisions and interactions with private payers such as Blue Cross Blue Shield Association, UnitedHealthcare, and Aetna.

Program Structure and Participation

Participation required oncology practices to form arrangements linking clinicians, hospitals, home health agencies, and specialty pharmacies, involving stakeholders such as National Association of Community Health Centers, Community Oncology Alliance, and national practice networks like Oncology Care Partners and US Oncology Network. Practices entered multi-year agreements with the Centers for Medicare & Medicaid Services and coordinated with organizations including American Hospital Association, Association of American Medical Colleges, and state Medicaid agencies like New York State Department of Health and California Department of Health Care Services. Patient attribution and eligibility intersected with rules from Social Security Administration benefit programs and guidance from Office of Inspector General and Department of Health and Human Services. Technical assistance and analytics were provided by vendors and contractors tied to firms such as McKinsey & Company, Deloitte, IBM Watson Health, Optum, and Epic Systems Corporation.

Payment Model and Cost Metrics

The payment model combined risk-adjusted prospective payments, fee-for-service reconciliation, and performance-based payments, drawing on benchmarking approaches used in Bundled Payments for Care Improvement and concepts from Capitation pilots. Cost metrics included total cost of care, emergency department utilization, hospitalizations, and intravenous chemotherapy episode costs, relying on claims algorithms similar to those used by Centers for Medicare & Medicaid Services in other initiatives and analytical methods from Agency for Healthcare Research and Quality and RAND Corporation. Benchmarks were influenced by regional spending patterns documented by Dartmouth Atlas of Health Care, and actuarial inputs from firms like Milliman and PwC informed target setting. Financial arrangements required interactions with federal statutes such as Medicare Prescription Drug, Improvement, and Modernization Act and compliance with regulations overseen by Office of Management and Budget.

Quality Measures and Patient Outcomes

Quality measures combined process, outcome, and patient-reported metrics including chemotherapy care management, timely initiation, avoidable hospitalizations, hospice utilization, and patient experience instruments connected to tools developed by National Quality Forum, Agency for Healthcare Research and Quality, and the Patient-Reported Outcomes Measurement Information System. Measures tied to cancer-specific guidelines referenced standards from National Comprehensive Cancer Network, American Society of Clinical Oncology, and tumor-specific societies like American Society for Radiation Oncology and Society of Gynecologic Oncology. Patient outcome assessments intersected with survivorship frameworks from Centers for Disease Control and Prevention and palliative care guidance from National Hospice and Palliative Care Organization and clinical trial endpoints common to National Cancer Institute cooperative groups.

Implementation and Provider Experience

Implementation challenges and provider experience were documented in case studies from academic centers including University of California San Francisco Medical Center, Massachusetts General Hospital, Stanford Health Care, and community practices affiliated with networks such as GenesisCare and Community Oncology Alliance members. Operational issues involved electronic health records from vendors like Epic Systems Corporation, Cerner Corporation, and Allscripts Healthcare Solutions, care coordination with Home Instead Senior Care and specialty pharmacy models exemplified by CVS Health and Walgreens Boots Alliance, and workforce implications discussed by Association of Community Cancer Centers and labor analyses from American Hospital Association.

Criticisms and Impact Studies

Critiques emerged from academic evaluations published by researchers at Harvard Medical School, Yale School of Medicine, Johns Hopkins Bloomberg School of Public Health, and policy analysts at Kaiser Family Foundation and Commonwealth Fund, questioning savings magnitude, selection effects, and administrative burden. Empirical impact studies compared spending and outcomes to control groups using methods from RAND Corporation and National Bureau of Economic Research, with findings debated in forums such as Health Affairs and conferences hosted by American Society of Clinical Oncology and AcademyHealth. Legal and ethical discussions invoked stakeholders including Office of Inspector General and advocacy groups like Patient Advocate Foundation and raised concerns similar to debates around Bundled Payments for Care Improvement and other alternative payment models.

Category:Medicare payment models